8-Hydroxy-PIPAT oxalate

Discontinued Product

8-Hydroxy-PIPAT oxalate (Cat. No. 0797) has been withdrawn from sale for commercial reasons.
Cat.No. 0797 - 8-Hydroxy-PIPAT oxalate | C16H22INO.C2H2O4 | CAS No. 1451210-48-2
Description: High affinity 5-HT1A agonist
Chemical Name: (RS)-trans-8-Hydroxy-2-[N-n-propyl-N-(3'-iodo-2'-propenyl)amino]tetralin oxalate
Purity: ≥98% (HPLC)
Datasheet
Citations
Reviews
Literature (5)

Biological Activity for 8-Hydroxy-PIPAT oxalate

8-Hydroxy-PIPAT oxalate is a high affinity 5-HT1A receptor agonist (Kd = 0.38 nM).

7-Hydroxy Isomer also available.

Licensing Information

Sold with the permission of the University of Pennsylvania

Technical Data for 8-Hydroxy-PIPAT oxalate

M. Wt 461.3
Formula C16H22INO.C2H2O4
Storage Desiccate at -20°C
Purity ≥98% (HPLC)
CAS Number 1451210-48-2
PubChem ID 56972162
InChI Key XIBSIFOFYWBOAQ-JOKMOOFLSA-N
Smiles [H]OC(=O)C(=O)O[H].CCCN(C\C=C\I)C1CCC2=CC=CC(O)=C2C1

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Tocris products are intended for laboratory research use only, unless stated otherwise.

Product Datasheets for 8-Hydroxy-PIPAT oxalate

References for 8-Hydroxy-PIPAT oxalate

References are publications that support the biological activity of the product.

Zhuang et al (1993) Synthesis of (R,S)-trans-8-Hydroxy-2-[N-n-propyl-N-(3'-iodo-2'-propenyl)amino]tetralin (trans-8-OH-PIPAT): a new 5-HT1A receptor ligand. J.Med.Chem. 36 3161 PMID: 8230102

View Related Products by Target

View Related Products by Product Action

View all 5-HT1A Receptor Agonists

Keywords: 8-Hydroxy-PIPAT oxalate, 8-Hydroxy-PIPAT oxalate supplier, High, affinity, 5-HT1A, agonists, Serotonin, Receptors, 0797, Tocris Bioscience

Citations for 8-Hydroxy-PIPAT oxalate

Citations are publications that use Tocris products.

Currently there are no citations for 8-Hydroxy-PIPAT oxalate.

Reviews for 8-Hydroxy-PIPAT oxalate

There are currently no reviews for this product. Be the first to review 8-Hydroxy-PIPAT oxalate and earn rewards!

Have you used 8-Hydroxy-PIPAT oxalate?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Literature in this Area

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!

*Please note that Tocris will only send literature to established scientific business / institute addresses.


GPCR

GPCR Product Listing

A collection of over 450 products for G protein-coupled receptors, the listing includes research tools for the study of:

  • Rhodopsin-like Receptors
  • Glutamate Receptors
  • Frizzled Receptors
  • GPCR Signaling
Neurodegeneration

Neurodegeneration Product Guide

A collection of over 275 products for neurodegeneration research, the guide includes research tools for the study of:

  • Alzheimer's disease
  • Parkinson's disease
  • Huntington's disease
5-HT Receptors

5-HT Receptors Scientific Review

Written by Nicholas M. Barnes and John F. Neumaier, this review summarizes the various serotonin receptor subtypes and their importance in mediating the role of serotonin in numerous physiological and pharmacological processes. Compounds available from Tocris are listed.

Depression

Depression Poster

Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.

Parkinson's

Parkinson's Poster

Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.